Novavax and Commonwealth of Australia announce agreement in principle for acquisition of Novavax COVID-19 vaccine
- Details
- Category: Business and Industry
Novavax, Inc. (Nasdaq: NVAX), a late stage biotechnology company developing next-generation vaccines for serious infectious diseases, announced the signing of a non-binding Heads of Terms document with the Australian Government to supply 40 million doses of the Company’s COVID-19 vaccine candidate, NVX-CoV2373, for the Australian community.
Data for Lilly's bamlanivimab (LY-CoV555) in COVID-19 outpatients published in New England Journal of Medicine
- Details
- Category: Eli Lilly and Company
The New England Journal of Medicine has published data from the monotherapy arms of BLAZE-1, a Phase 2 study assessing the efficacy and safety of Eli Lilly and Company's (NYSE: LLY) bamlanivimab (LY-CoV555) - a neutralizing antibody - in the COVID-19 outpatient setting.
Novartis announces collaboration with Molecular Partners to develop two DARPin® therapies designed for potential use against COVID-19
- Details
- Category: Novartis
Novartis and Molecular Partners AG announced a collaboration in the form of an option and license agreement to develop, manufacture and commercialize Molecular Partners' anti-COVID-19 DARPin® program, consisting of two therapeutic candidates, MP0420 and MP0423. The collaboration aims to leverage Molecular Partners' proprietary DARPin® technologies and Novartis broad expertise in
Novavax announces facility expansion to support global vaccine development
- Details
- Category: Business
Novavax, Inc. (Nasdaq: NVAX), a late-stage biotechnology company developing next-generation vaccines for serious infectious diseases, today announced the expansion of its Maryland campus to accommodate the company's rapid growth as it works to develop its candidate vaccine against COVID-19 and advance its influenza vaccine for global markets.
RDIF and União Química file documents for registration of Sputnik V vaccine with regulator in Brazil
- Details
- Category: Business
The Russian Direct Investment Fund (RDIF, Russia's sovereign wealth fund), União Química Farmacêutica Nacional and the Government of the State of Paraná announce the pre-submission of preliminary documents to Brazil's National Health Surveillance Agency (ANVISA), in order to register Russia's Sputnik V vaccine, the world's first registered vaccine against coronavirus infection, in conformity with the Brazilian regulatory procedures.
Takeda expands COVID-19 vaccine supply in Japan through partnership with Moderna and Government of Japan
- Details
- Category: Takeda
Takeda Pharmaceutical Company Limited (TSE:4502/NYSE:TAK) ("Takeda") today announced that it will import and distribute 50 million doses of Moderna's COVID-19 vaccine candidate, mRNA-1273, starting in the first half of 2021, pending licensure in Japan. This effort is part of a three-way agreement among Takeda, Moderna and the Government of Japan's Ministry of Health Labour and Welfare (MHLW).
Roche announces collaboration with Atea Pharmaceuticals to develop a potential oral treatment for COVID-19 patients
- Details
- Category: Roche
Roche (SIX: RO, ROG; OTCQX: RHHBY) and Atea Pharmaceuticals, Inc. announced that they are joining forces in the fight against COVID-19 to develop, manufacture and distribute AT-527, Atea’s investigational oral direct-acting antiviral, to people around the globe. AT-527 acts by blocking the viral RNA polymerase enzyme needed for viral replication, and is currently being studied in a Phase 2 clinical trial for hospitalised patients with moderate COVID-19.
More Pharma News ...
- Sanofi and GSK to support COVAX with 200 million doses of adjuvanted, recombinant protein-based COVID-19 vaccine
- Russian application of Sputnik V vaccine for WHO vaccine prequalification among the first applications submitted
- Novavax provides Phase 3 COVID-19 vaccine clinical development update
- Johnson & Johnson prepares to resume Phase 3 ENSEMBLE Trial of its Janssen COVID-19 vaccine candidate in the U.S.
- Moderna announces supply agreement with the Ministry of Public Health to supply Qatar with mRNA vaccine against COVID-19 (mRNA-1273)
- FDA authorises restart of the COVID-19 AZD1222 vaccine US Phase III trial
- CureVac reports positive preclinical data for its COVID-19 vaccine candidate, CVnCoV